Anebulo Pharmaceuticals Inc (ANEB)

$0.95 +0.00 (0.01%)
Market Cap 43.14M
Revenue (ttm) 0.00
Net Income (ttm) -8.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 33,031
Avg Vol 81,010
Day's Range N/A - N/A
Shares Out 41.09M
Stochastic %K 50%
Beta -0.81
Analysts Sell
Price Target $3.00

Company Profile

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceut...

Industry: Biotechnology
Sector: Healthcare
Phone: 512 598 0931
Address:
1017 Ranch Road 620 South, Suite 107, Lakeway, United States
DummiesNixGerafft
DummiesNixGerafft Feb. 4 at 7:58 PM
Die aktuellen Raketen $GUTS $LITS $ASMB $ANEB
0 · Reply
Smoothopera1or
Smoothopera1or Jan. 31 at 1:45 PM
$ANEB avg price target is between 5-8$ bullish long term.
0 · Reply
Smoothopera1or
Smoothopera1or Jan. 31 at 1:44 PM
$ANEB The company’s lack of debt provides flexibility to fund operations and R&D without heavy interest burdens, a plus for clinical-stage biotech firms that often spend years without revenue.
0 · Reply
Smoothopera1or
Smoothopera1or Jan. 31 at 1:44 PM
$ANEB Institutional and Investor Interest
0 · Reply
Smoothopera1or
Smoothopera1or Jan. 31 at 1:43 PM
$ANEB
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 27 at 12:03 PM
$ANEB RSI: 42.86, MACD: -0.1932 Vol: 0.06, MA20: 1.10, MA50: 1.76 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 29 at 11:36 PM
$ANEB RSI: 17.38, MACD: -0.3049 Vol: 0.48, MA20: 2.01, MA50: 2.31 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
fantastex
fantastex Dec. 27 at 12:13 PM
some body explain me the tender offer stufa at 3.50 dolalrs? $ANEB why this Is at 1.14?
1 · Reply
DARKP00L
DARKP00L Dec. 26 at 5:20 PM
$ANEB 12:00 on Dec. 26 2025 How Is The Market Feeling About Anebulo Pharmaceuticals Inc? #tradeideas
0 · Reply
itsbilly
itsbilly Dec. 25 at 5:18 PM
$ANEB got my offer closing on the 23rd seems like easy money
1 · Reply
Latest News on ANEB
Anebulo Pharmaceuticals Announces Final Results of Tender Offer

Jan 29, 2026, 9:00 AM EST - 6 days ago

Anebulo Pharmaceuticals Announces Final Results of Tender Offer

Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer

Jan 27, 2026, 9:00 AM EST - 8 days ago

Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer

Anebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender Offer

Dec 22, 2025, 9:00 AM EST - 6 weeks ago

Anebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender Offer

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates

Nov 13, 2025, 4:05 PM EST - 2 months ago

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates

Sep 29, 2025, 4:05 PM EDT - 4 months ago

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates

Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity

Sep 25, 2025, 7:30 AM EDT - 4 months ago

Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity

Anebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives

Sep 12, 2025, 7:30 AM EDT - 5 months ago

Anebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives

Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock

Jul 23, 2025, 8:00 AM EDT - 7 months ago

Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Updates

May 13, 2025, 4:05 PM EDT - 9 months ago

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Updates

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates

Feb 14, 2025, 4:05 PM EST - 1 year ago

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates

Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise

Dec 23, 2024, 9:15 AM EST - 1 year ago

Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates

Nov 13, 2024, 4:05 PM EST - 1 year ago

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates

Sep 25, 2024, 4:05 PM EDT - 1 year ago

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates

Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects

Jul 22, 2024, 7:00 AM EDT - 1 year ago

Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects

Galehead Development to Collaborate With Rivian Automotive on Renewable Energy Project Development

May 15, 2024, 1:15 PM EDT - 1 year ago

Galehead Development to Collaborate With Rivian Automotive on Renewable Energy Project Development

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates

May 15, 2024, 1:05 PM EDT - 1 year ago

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates

Feb 13, 2024, 4:05 PM EST - 2 years ago

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates

Nov 14, 2023, 4:05 PM EST - 2 years ago

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates

Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors

Oct 6, 2023, 4:06 PM EDT - 2 years ago

Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors

Anebulo Pharmaceuticals Announces New CEO

Oct 6, 2023, 4:06 PM EDT - 2 years ago

Anebulo Pharmaceuticals Announces New CEO

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates

Sep 20, 2023, 4:29 PM EDT - 2 years ago

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates

Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences

Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates

May 11, 2023, 8:00 AM EDT - 2 years ago

Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates

Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication

Mar 28, 2023, 8:00 AM EDT - 3 years ago

Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals Expands its Integrated and Outsourced Solutions

Mar 8, 2023, 8:00 AM EST - 3 years ago

Anebulo Pharmaceuticals Expands its Integrated and Outsourced Solutions

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates

Feb 10, 2023, 8:38 AM EST - 3 years ago

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates

Anebulo: Interesting Drug For Cannabis Intoxication, But The Market Potential Remains Unclear

Jan 27, 2023, 3:49 PM EST - 3 years ago

Anebulo: Interesting Drug For Cannabis Intoxication, But The Market Potential Remains Unclear

Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication

Jan 9, 2023, 8:00 AM EST - 3 years ago

Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates

Nov 10, 2022, 8:00 AM EST - 3 years ago

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates

Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors

Nov 1, 2022, 4:00 PM EDT - 3 years ago

Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors

Anebulo Pharmaceuticals Announces $6.6 Million Private Placement Financing

Sep 26, 2022, 7:00 AM EDT - 3 years ago

Anebulo Pharmaceuticals Announces $6.6 Million Private Placement Financing

Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

Sep 26, 2022, 7:00 AM EDT - 3 years ago

Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals to Webcast R&D Day on September 26, 2022

Sep 20, 2022, 8:00 AM EDT - 3 years ago

Anebulo Pharmaceuticals to Webcast R&D Day on September 26, 2022

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Highlights Recent Business Progress

Sep 9, 2022, 8:00 AM EDT - 3 years ago

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Highlights Recent Business Progress

Anebulo Pharmaceuticals to Host Inaugural R&D Day in New York City on Monday, September 26

Aug 23, 2022, 5:00 PM EDT - 3 years ago

Anebulo Pharmaceuticals to Host Inaugural R&D Day in New York City on Monday, September 26

Anebulo's ANEB-001 Reduces Cannabis Intoxication In Healthy Participants

Jul 5, 2022, 8:00 AM EDT - 3 years ago

Anebulo's ANEB-001 Reduces Cannabis Intoxication In Healthy Participants

Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

Jul 5, 2022, 6:00 AM EDT - 3 years ago

Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022

Jun 23, 2022, 4:00 PM EDT - 3 years ago

Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022

Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer

May 24, 2022, 4:00 PM EDT - 4 years ago

Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates

May 11, 2022, 9:00 AM EDT - 4 years ago

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates

Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of a Phase 2 Clinical Trial and Provides Guidance on IND Submission

Apr 1, 2022, 7:00 AM EDT - 4 years ago

Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of a Phase 2 Clinical Trial and Provides Guidance on IND Submission

Anebulo Pharmaceuticals Reports Q2 Financial Results, Plans To Develop Therapy For Acute Cannabinoid Intoxication

Feb 11, 2022, 9:13 AM EST - 4 years ago

Anebulo Pharmaceuticals Reports Q2 Financial Results, Plans To Develop Therapy For Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2022 Financial Results and Recent Updates

Feb 11, 2022, 8:00 AM EST - 4 years ago

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2022 Financial Results and Recent Updates

Anebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public Relations

Jan 6, 2022, 7:00 AM EST - 4 years ago

Anebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public Relations

Anebulo Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference

Jan 6, 2022, 7:00 AM EST - 4 years ago

Anebulo Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference

Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director

Jan 4, 2022, 7:00 AM EST - 4 years ago

Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director

Anebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication

Jan 3, 2022, 7:00 AM EST - 4 years ago

Anebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update

Nov 12, 2021, 8:00 AM EST - 4 years ago

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update

Anebulo Pharmaceuticals Announces Issuance of U.S. Patent Covering Use of ANEB-001 for the Treatment of Acute Cannabinoid Overdose

Oct 13, 2021, 8:00 AM EDT - 4 years ago

Anebulo Pharmaceuticals Announces Issuance of U.S. Patent Covering Use of ANEB-001 for the Treatment of Acute Cannabinoid Overdose

Overdose Unknown: How Anebulo Pharmaceuticals Is Working to Solve a Growing Marijuana Overdose Problem

Oct 12, 2021, 8:59 AM EDT - 4 years ago

Overdose Unknown: How Anebulo Pharmaceuticals Is Working to Solve a Growing Marijuana Overdose Problem

DummiesNixGerafft
DummiesNixGerafft Feb. 4 at 7:58 PM
Die aktuellen Raketen $GUTS $LITS $ASMB $ANEB
0 · Reply
Smoothopera1or
Smoothopera1or Jan. 31 at 1:45 PM
$ANEB avg price target is between 5-8$ bullish long term.
0 · Reply
Smoothopera1or
Smoothopera1or Jan. 31 at 1:44 PM
$ANEB The company’s lack of debt provides flexibility to fund operations and R&D without heavy interest burdens, a plus for clinical-stage biotech firms that often spend years without revenue.
0 · Reply
Smoothopera1or
Smoothopera1or Jan. 31 at 1:44 PM
$ANEB Institutional and Investor Interest
0 · Reply
Smoothopera1or
Smoothopera1or Jan. 31 at 1:43 PM
$ANEB
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 27 at 12:03 PM
$ANEB RSI: 42.86, MACD: -0.1932 Vol: 0.06, MA20: 1.10, MA50: 1.76 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 29 at 11:36 PM
$ANEB RSI: 17.38, MACD: -0.3049 Vol: 0.48, MA20: 2.01, MA50: 2.31 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
fantastex
fantastex Dec. 27 at 12:13 PM
some body explain me the tender offer stufa at 3.50 dolalrs? $ANEB why this Is at 1.14?
1 · Reply
DARKP00L
DARKP00L Dec. 26 at 5:20 PM
$ANEB 12:00 on Dec. 26 2025 How Is The Market Feeling About Anebulo Pharmaceuticals Inc? #tradeideas
0 · Reply
itsbilly
itsbilly Dec. 25 at 5:18 PM
$ANEB got my offer closing on the 23rd seems like easy money
1 · Reply
Uberkikz11
Uberkikz11 Dec. 24 at 6:13 PM
$ANEB nibbled on some shares from $1.15-$1.18 to tender & in anticipation of a lowered reverse split going dark later in 2026
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 24 at 11:18 AM
$ANEB
0 · Reply
itsphd
itsphd Dec. 24 at 3:10 AM
$ANEB If there was a share buyback why in the world did this fall under the share buyback price??
0 · Reply
UgoGreg
UgoGreg Dec. 22 at 7:49 PM
$ANEB https://youtu.be/Pga-Rf9NLOY
0 · Reply
longandon
longandon Dec. 22 at 7:07 PM
$ANEB wow this sucks. Though I cut my loss several months earlier, but now y'all bulls really wanna go private? Such a shady deal and cutting out the reverse split now. All those that accumulated before gonna sell. Contemplating short but wonder if it's worth it.
0 · Reply
Iman133
Iman133 Dec. 22 at 4:38 PM
$ANEB I am happy that I did not increase my position here. Such a weird stock. I won’t sell and will keep it until it goes private.
0 · Reply
DARKP00L
DARKP00L Dec. 22 at 2:23 PM
$ANEB 09:05 on Dec. 22 2025 Anebulo To Commence $3.50/Shr Cash Tender Offer For Up To 300K Shares As Part Of Plan To Go Private In Lieu Of Reverse Stock Split At Ratio Of Not Less Than 1-For-2,500 And Not Greater Than 1-For-7,500 #tradeideas
0 · Reply
mikedumbledar
mikedumbledar Dec. 22 at 2:21 PM
$ANEB lots of people gonna lose $ on this deal
1 · Reply
premarketmaker
premarketmaker Dec. 22 at 2:11 PM
$ANEB to go private at $3.50 per share
0 · Reply
Dieseld28
Dieseld28 Dec. 22 at 2:09 PM
$AZI $ANEB same news
0 · Reply
premarketmaker
premarketmaker Dec. 22 at 2:07 PM
$ANEB looks like a buy back at $3.50 per share/300K
0 · Reply
premarketmaker
premarketmaker Dec. 22 at 2:06 PM
$ANEB Voluntary Self Tender consists of acquiring up to 300,000 shares at $3.50 price per share
0 · Reply